Thyrotoxic Heart Failure: A Narrative Review of Pathophysiology and Principle Management
Main Article Content
Abstract
Heart failure is one of the most common causes of morbidity and mortality worldwide. Several studies showed that hyperthyroidism is a potentially reversible cause of heart failure and should be excluded in every heart failure patient, especially in the absence of a common cause of heart failure and structural heart disease. The diagnosis approach of thyrotoxic heart failure still remains a lack of specific guidelines. It is necessary to establish a thyroid dysfunction evidence accompanied by a structural and functional heart abnormality. Several studies have shown that cardiac dysfunction and heart failure, which related to hyperthyroidism, will be resolved in less than six months after a patient has reached euthyroid state. This narrative review summarizes the literature on the pathophysiology and principle management of thyrotoxic heart failure.
Downloads
Article Details
References
Sionis A. Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol (Engl Ed). 2016;69(12):1119–25.
Mitchell JE. Emerging Role of Anemia in Heart Failure. Am J Cardiol. 2007;99(6 SUPPL. 2):15–20.
Lam CSP. Heart failure in Southeast Asia: facts and numbers. ESC Hear Fail. 2015;2(2):46–9.
Osuna PM, Udovcic M, Sharma MD. Hyperthyroidism and the Heart. Methodist Debakey Cardiovasc J. 2017;13(2):60–3.
Siu CW, Yeung CY, Lau CP, Kung AWC, Tse HF. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart. 2007;93(4):483–7.
Pirahanchi Y, Jialal I. Physiology, Thyroid Stimulating Hormone (TSH) [Internet]. StatPearls. StatPearls Publishing; 2018 [cited 02 Mei 2020]. Available at: http://www.ncbi.nlm.nih.gov/pubmed/29763025
Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. 2014; 94(2):355–82.
Sinha R, Yen PM. Cellular Action of Thyroid Hormone [Internet]. Endotext. MDText.com, Inc.; 2000 [cited 01 Desember 2020]. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25905423
Jameson JL. Harrison’s endocrinology, 4th edition. New York: McGraw-Hill Education Medical; 2017.
Dahl P, Danzi S, Klein I. Thyrotoxic cardiac disease. Curr Heart Fail Rep. 2008;5(3):170–6.
Ertek S, Cicero AF. Hyperthyroidism and cardiovascular complications: A narrative review on the basis of pathophysiology. Arch Med Sci. 2013;9(5):944–52.
Galli E, Pingitore A, Iervasi G. The role of thyroid hormone in the pathophysiology of heart failure: Clinical evidence. Heart Fail Rev. 2010;15(2):155– 69.
Klemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ, et al. Thyroid Hormone Treatment after Coronary-Artery Bypass Surgery. N Engl J Med. Desember 1995;333(23):1522–7.
Razvi S, Jabbar A, Pingitore A, Danzi S, Biondi B, Klein I, et al. Thyroid Hormones and Cardiovascular Function and Diseases. J Am Coll Cardiol. April 2018;71(16):1781–96.
Carrillo-Sepúlveda MA, Ceravolo GS, Fortes ZB, Carvalho MH, Tostes RC, Laurindo FR, et al. Thyroid hormone stimulates NO production via activation of the PI3K/Akt pathway in vascular myocytes. Cardiovasc Res. Februarie 2010;85(3):560–70.
Vicinanza R, Coppotelli G, Malacrino C, Nardo T, Buchetti B, Lenti L, et al. Oxidized Low- Density Lipoproteins Impair Endothelial Function by Inhibiting Non-Genomic Action of Thyroid Hormone–Mediated Nitric Oxide Production in Human Endothelial Cells. Thyroid. Oktober 2012;23(2):231–8.
von Hafe M, Neves JS, Vale C, Borges-Canha M, Leite-Moreira A. The impact of thyroid hormone dysfunction on ischemic heart disease. Endocr Connect. Mei 2019;8(5):R76–90.
Davis PJ, Mousa FBD and SA. Thyroid Hormone- Induced Angiogenesis. Vol 5, Current Cardiology Reviews. 2009. bl 12–6.
Tobias E, David K, Rainer L, C. EKK, K. EH. Hypoxia- Inducible Factor-1 Is Central to Cardioprotection. Circulation. Julie 2008;118(2):166–75.
Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, Banach M. The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res. 2009;2(1):4.
Albakri A. Thyrotoxic heart failure: A review of clinical status and meta-analysis of electrocardiogram diagnosis and medical clinical management methods. Integr Mol Med. 2019;5(6):1–11.
Babenko AY, Bairamov AA, Grineva EN, Ulupova EO. Thyrotoxic Cardiomyopathy. In: Cardiomyopathies - From Basic Research to Clinical Management [Internet]. InTech; 2012. bl 553–80. Available at: www.intechopen.com
Pantos C, Mourouzis I, Cokkinos D V. New insights into the role of thyroid hormone in cardiac remodeling: Time to reconsider? Heart Fail Rev. 2011;16(1):79–96.
Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725–35.
Iervasi G, Nicolini G. Thyroid hormone and cardiovascular system: From basic concepts to clinical application. Intern Emerg Med. 2013;8(SUPPL. 1):71–4.
Palmieri EA, Fazio S, Palmieri V, Lombardi G, Biondi B. Myocardial contractility and total arterial stiffness in patients with overt hyperthyroidism: acute effects of beta1-adrenergic blockade. Eur J Endocrinol Eur J Endocrinol. 150(6):757–62.
Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol. 2010;6(8):431–43.
Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC, Hansen PR, et al. Subclinical and Overt Thyroid Dysfunction and Risk of All-Cause Mortality and Cardiovascular Events: A Large Population Study. J Clin Endocrinol Metab. Julie 2014;99(7):2372–82.
Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7(4):167–86.
Wang W, Guan H, Fang W, Zhang K, Gerdes AM, Iervasi G, et al. Free triiodothyronine level correlates with myocardial injury and prognosis in idiopathic dilated cardiomyopathy: Evidence from cardiac MRI and SPECT/PET imaging. Sci Rep. 2016;6:39811.
Ascheim DD, Hryniewicz K. Thyroid hormone metabolism in patients with congestive heart failure: The low triiodothyronine state. Thyroid. 2002;12(6):511–5.
Kannan L, Shaw PA, Morley MP, Brandimarto J, Fang JC, Sweitzer NK, et al. Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes. Circ Heart Fail. 2018;11(12):e005266.
Jabbar A, Pingitore A, Pearce SHS, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol. 2016;14(1):39–55.
Frey A, Kroiss M, Berliner D, Seifert M, Allolio B, Güder G, et al. Prognostic impact of subclinical thyroid dysfunction in heart failure. Int J Cardiol. 2013;168(1):300–5.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution. Eur J Heart Fail. 2016;18(8):891–975.
De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388(10047):906–18.
Smit JWA, Eustatia-Rutten CFA, Corssmit EPM, Pereira AM, Frölich M, Bleeker GB, et al. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: A randomized, placebo-controlled study. J Clin Endocrinol Metab. 2005;90(11):6041–7.
Oliveros-Ruiz L, Vallejo M, Diez Canseco LF, Cárdenas M, Hermosillo JAG. Determinants of Thyrotoxic Cardiomyopathy Recovery. Biomed Res Int. 2013;2013:1–7.
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343– 421.
Reddy V, Taha W, Kundumadam S, Khan M. Atrial fibrillation and hyperthyroidism: A literature review. Indian Heart J. 2017;69(4):545–50.